{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T04:09:47Z","timestamp":1773115787694,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UG3\/UH3AI133669"],"award-info":[{"award-number":["UG3\/UH3AI133669"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"NIMH","doi-asserted-by":"crossref","award":["F31MH124582"],"award-info":[{"award-number":["F31MH124582"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s10461-024-04561-2","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T14:14:41Z","timestamp":1733408081000},"page":"804-816","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Preference for Long-Acting HIV Prevention Methods Among Transgender Women Vulnerable to HIV in Eastern and Southern United States: Findings from the LITE Study"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9563-1822","authenticated-orcid":false,"given":"Erin E.","family":"Cooney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meg","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo A.","family":"Aguayo-Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genesis","family":"Valera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tonia C.","family":"Poteat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth H.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Beyrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keri N.","family":"Althoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asa E.","family":"Radix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Wawrzyniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason S.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn A.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vani","family":"Vannappagari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leigh","family":"Ragone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemiek","family":"de Ruiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sari L.","family":"Reisner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea L.","family":"Wirtz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"4561_CR1","unstructured":"Administration USFaD. FDA approves first drug for reducing the risk of sexually acquired HIV infection. 2012"},{"key":"4561_CR2","unstructured":"Administration USFD. FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention. 2021"},{"issue":"5","key":"4561_CR3","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1016\/S2352-3018(23)00008-5","volume":"10","author":"AL Wirtz","year":"2023","unstructured":"Wirtz AL, Humes E, Althoff KN, et al. HIV incidence and mortality in transgender women in the eastern and southern USA: a multisite cohort study. Lancet HIV. 2023;10(5):e308\u201319.","journal-title":"Lancet HIV"},{"issue":"1","key":"4561_CR4","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1097\/QAI.0000000000002315","volume":"84","author":"W McFarland","year":"2020","unstructured":"McFarland W, Wesson P, Turner C, et al. High HIV incidence among young and racial\/ethnic minority transgender women in San Francisco: results of a longitudinal cohort study. J Acquir Immune Defic Syndr. 2020;84(1):e7\u201310.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"4561_CR5","unstructured":"CDC. Diagnoses of HIV Infection in the United States and Dependent Areas, 2021, 2023"},{"key":"4561_CR6","unstructured":"Prevention CfDCa. Estimated HIV incidence and prevalence in the United States, 2018\u20132022. . HIV Surveillance Supplemental Report May 2024; 29(1)"},{"key":"4561_CR7","unstructured":"CDC. Diagnoses of HIV Infection in the United States and Dependent Areas, 2019, 2021"},{"key":"4561_CR8","unstructured":"Prevention CfDCa. HIV Surveillance Report, 2018 (Updated), May 2020"},{"issue":"1","key":"4561_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12981-023-00556-6","volume":"20","author":"EE Cooney","year":"2023","unstructured":"Cooney EE, Footer KHA, Glick JL, Passaniti A, Howes M, Sherman SG. Understanding the social and structural context of oral PrEP delivery: an ethnography exploring barriers and facilitators impacting transgender women who engage in street-based sex work in Baltimore, Maryland. AIDS Res Ther. 2023;20(1):69.","journal-title":"AIDS Res Ther"},{"key":"4561_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annepidem.2022.03.016","volume":"70","author":"EE Cooney","year":"2022","unstructured":"Cooney EE, Reisner SL, Saleem HT, et al. Prevention-effective adherence trajectories among transgender women indicated for PrEP in the United States: a prospective cohort study. Ann Epidemiol. 2022;70:23\u201331.","journal-title":"Ann Epidemiol"},{"issue":"1","key":"4561_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12889-021-12425-w","volume":"22","author":"SB Bass","year":"2022","unstructured":"Bass SB, Kelly PJ, Brajuha J, et al. Exploring barriers and facilitators to PrEP use among transgender women in two urban areas: implications for messaging and communication. BMC Public Health. 2022;22(1):17.","journal-title":"BMC Public Health"},{"issue":"5","key":"4561_CR12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/09540121.2019.1659912","volume":"32","author":"SR Cahill","year":"2020","unstructured":"Cahill SR, Keatley J, Wade Taylor S, et al. \u201cSome of us, we don\u2019t know where we\u2019re going to be tomorrow\u201d. Contextual factors affecting PrEP use and adherence among a diverse sample of transgender women in San Francisco. AIDS Care. 2020;32(5):585\u201393.","journal-title":"AIDS Care"},{"issue":"2","key":"4561_CR13","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1080\/09540121.2020.1769835","volume":"33","author":"O Nieto","year":"2021","unstructured":"Nieto O, Fehrenbacher AE, Cabral A, Landrian A, Brooks RA. Barriers and motivators to pre-exposure prophylaxis uptake among Black and Latina transgender women in Los Angeles: perspectives of current PrEP users. AIDS Care. 2021;33(2):244\u201352.","journal-title":"AIDS Care"},{"issue":"5","key":"4561_CR14","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1007\/s10461-019-02703-5","volume":"24","author":"CT Rael","year":"2020","unstructured":"Rael CT, Martinez M, Giguere R, et al. Transgender women\u2019s concerns and preferences on potential future long-acting biomedical HIV prevention strategies: the case of injections and implanted medication delivery devices (IMDDs). AIDS Behav. 2020;24(5):1452\u201362.","journal-title":"AIDS Behav"},{"issue":"3","key":"4561_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/COH.0000000000000734","volume":"17","author":"O Sued","year":"2022","unstructured":"Sued O, Nardi N, Spadaccini L. Key population perceptions and opinions about long-acting antiretrovirals for prevention and treatment: a scoping review. Curr Opin HIV AIDS. 2022;17(3):145\u201361.","journal-title":"Curr Opin HIV AIDS"},{"issue":"2","key":"4561_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1089\/apc.2023.0211","volume":"38","author":"PW Schnarrs","year":"2024","unstructured":"Schnarrs PW, Zuniga J, Benitez G, et al. Intention to use different formulations of longer acting HIV pre-exposure prophylaxis among transgender and gender expansive individuals: the roles of social vulnerability and medical mistrust. AIDS Patient Care STDS. 2024;38(2):51\u201360.","journal-title":"AIDS Patient Care STDS"},{"issue":"5","key":"4561_CR17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s11904-021-00571-0","volume":"18","author":"R Logan","year":"2021","unstructured":"Logan R, Seidman D. Lessons learned from longer acting reversible contraception applied to longer acting HIV prevention technologies. Curr HIV\/AIDS Rep. 2021;18(5):483\u20138.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"4","key":"4561_CR18","doi-asserted-by":"publisher","DOI":"10.2196\/29152","volume":"10","author":"AL Wirtz","year":"2021","unstructured":"Wirtz AL, Cooney EE, Stevenson M, et al. Digital epidemiologic research on multilevel risks for HIV acquisition and other health outcomes among transgender women in Eastern and Southern United States: protocol for an online cohort. JMIR Res Protocols. 2021;10(4): e29152.","journal-title":"JMIR Res Protocols"},{"issue":"10","key":"4561_CR19","doi-asserted-by":"publisher","DOI":"10.2196\/14704","volume":"8","author":"AL Wirtz","year":"2019","unstructured":"Wirtz AL, Poteat T, Radix A, et al. American cohort to study HIV acquisition among transgender women in high-risk areas (The LITE Study): protocol for a multisite prospective cohort study in the Eastern and Southern United States. JMIR Res Protocols. 2019;8(10): e14704.","journal-title":"JMIR Res Protocols"},{"issue":"1","key":"4561_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/QAI.0000000000002726","volume":"88","author":"J Malone","year":"2021","unstructured":"Malone J, Reisner SL, Cooney EE, et al. Perceived HIV acquisition risk and low uptake of PrEP among a cohort of transgender women with PrEP indication in the Eastern and Southern United States. J Acquir Immune Defic Syndr. 2021;88(1):10\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"4561_CR21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ejor.2004.04.032","volume":"168","author":"TL Saaty","year":"2006","unstructured":"Saaty TL. Rank from comparisons and from ratings in the analytic hierarchy\/network processes. Eur J Oper Res. 2006;168(2):557\u201370.","journal-title":"Eur J Oper Res"},{"key":"4561_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1751-0473-3-17","volume":"3","author":"Z Bursac","year":"2008","unstructured":"Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008;3:17.","journal-title":"Source Code Biol Med"},{"issue":"9","key":"4561_CR23","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"HF Hsieh","year":"2005","unstructured":"Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277\u201388.","journal-title":"Qual Health Res"},{"issue":"12","key":"4561_CR24","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1007\/s10461-021-03357-y","volume":"25","author":"CT Rael","year":"2021","unstructured":"Rael CT, Lopez-R\u00edos J, McKenna SA, et al. Transgender women\u2019s barriers, facilitators, and preferences on tailored injection delivery strategies to administer long-acting injectable Cabotegravir (CAB-LA) for HIV pre-exposure prophylaxis (PrEP). AIDS Behav. 2021;25(12):4180\u201392.","journal-title":"AIDS Behav"},{"issue":"4","key":"4561_CR25","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/QAI.0000000000003135","volume":"92","author":"RP Matthews","year":"2023","unstructured":"Matthews RP, Zang X, Barrett SE, et al. A randomized, double-blind, placebo-controlled, phase 1 trial of radiopaque islatravir-eluting subdermal implants for pre-exposure prophylaxis against HIV-1 infection. JAIDS J Acquir Immune Defic Syndr. 2023;92(4):310\u20136.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"2","key":"4561_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/08964289.2019.1585325","volume":"45","author":"PA D'Avanzo","year":"2019","unstructured":"D\u2019Avanzo PA, Bass SB, Brajuha J, et al. Medical mistrust and PrEP perceptions among transgender women: a cluster analysis. Behav Med. 2019;45(2):143\u201352.","journal-title":"Behav Med"},{"issue":"2","key":"4561_CR27","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.2105\/AJPH.2014.302322","volume":"105","author":"LA Eaton","year":"2015","unstructured":"Eaton LA, Driffin DD, Kegler C, et al. The role of stigma and medical mistrust in the routine health care engagement of black men who have sex with men. Am J Public Health. 2015;105(2):e75-82.","journal-title":"Am J Public Health"},{"issue":"3","key":"4561_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.12927\/hcpap.2023.27192","volume":"21","author":"TC Poteat","year":"2023","unstructured":"Poteat TC, Maragh-Bass AC. Interrogating anti-blackness in US healthcare: contextual factors and policy implications. Healthcarepapers. 2023;21(3):43\u20138.","journal-title":"Healthcarepapers"},{"issue":"2","key":"4561_CR29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1089\/trgh.2019.0069","volume":"5","author":"MD Connolly","year":"2020","unstructured":"Connolly MD, Dankerlui DN, Eljallad T, Dodard-Friedman I, Tang A, Joseph CLM. Outcomes of a PrEP demonstration project with LGBTQ youth in a community-based clinic setting with integrated gender-affirming care. Transgend Health. 2020;5(2):75\u20139.","journal-title":"Transgend Health"},{"key":"4561_CR30","doi-asserted-by":"crossref","unstructured":"Morris E, Teplinskaya A, Olansky E, Rinderle JK, Chapin-Bardales J, National HIVBSATWSG. Characteristics Associated with Pre-Exposure Prophylaxis Discussion and Use Among Transgender Women Without HIV Infection - National HIV Behavioral Surveillance Among Transgender Women, Seven Urban Areas, United States, 2019\u20132020. MMWR Suppl 2024; 73(1): 9\u201320","DOI":"10.15585\/mmwr.su7301a2"},{"issue":"5","key":"4561_CR31","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1007\/s10461-022-03943-8","volume":"27","author":"A Zamantakis","year":"2023","unstructured":"Zamantakis A, Li DH, Benbow N, Smith JD, Mustanski B. Determinants of pre-exposure prophylaxis (PrEP) implementation in transgender populations: a qualitative scoping review. AIDS Behav. 2023;27(5):1600\u201318.","journal-title":"AIDS Behav"},{"issue":"2","key":"4561_CR32","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/QAI.0000000000002112","volume":"82","author":"T Poteat","year":"2019","unstructured":"Poteat T, Wirtz A, Malik M, et al. A gap between willingness and uptake: findings from mixed methods research on HIV prevention among black and Latina transgender women. J Acquir Immune Defic Syndr. 2019;82(2):131\u201340.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"10","key":"4561_CR33","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s40265-020-01313-z","volume":"80","author":"TC Poteat","year":"2020","unstructured":"Poteat TC, Radix A. HIV antiretroviral treatment and pre-exposure prophylaxis in transgender individuals. Drugs. 2020;80(10):965\u201372.","journal-title":"Drugs"},{"issue":"3","key":"4561_CR34","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s11904-020-00497-z","volume":"17","author":"JA Bauermeister","year":"2020","unstructured":"Bauermeister JA, Downs JS, Krakower DS. PrEP product acceptability and dual process decision-making among men who have sex with men. Curr HIV\/AIDS Rep. 2020;17(3):161\u201370.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"4561_CR35","unstructured":"Gengiah TN AKQ, Lewis L, Harkoo I, Mansoor LE, Khan J, et al. Phase I Safety, Tolerability and Pharmacokinetics of Tenofovir Alafenamide Implants in African Women. CROI 2024; 2024; Denver, CO; 2024. p. 25"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-024-04561-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-024-04561-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-024-04561-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T12:34:53Z","timestamp":1739795693000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-024-04561-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["4561"],"URL":"https:\/\/doi.org\/10.1007\/s10461-024-04561-2","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"19 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EEC, ALW, and TCP received funding support from ViiV healthcare to support this analysis through a grant to their institutions. VV, AdR, and LR are employed by ViiV Healthcare and receive stock from GSK. CAB was employed by ViiV Healthcare and received stock from GSK while this manuscript was in preparation. The remaining authors do not have declarations to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}